Viral Inactivation

REPORT HIGHLIGHTS

Global Viral Inactivation Market to Reach US$2.0 Billion by 2032

The global market for Viral Inactivation estimated at US$874.5 Million in the year 2025, is expected to reach US$2.0 Billion by 2032, growing at a CAGR of 12.4% over the analysis period 2025-2032. Kits & Reagents Component, one of the segments analyzed in the report, is expected to record a 14.1% CAGR and reach US$979.3 Million by the end of the analysis period. Growth in the Systems & Accessories Component segment is estimated at 11.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$258.9 Million While China is Forecast to Grow at 11.6% CAGR

The Viral Inactivation market in the U.S. is estimated at US$258.9 Million in the year 2025. China, the world`s second largest economy, is forecast to reach a projected market size of US$339.1 Million by the year 2032 trailing a CAGR of 11.6% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.8% and 10.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.0% CAGR.

Global Viral Inactivation Market - Key Trends & Drivers Summarized

Why Is Viral Inactivation Crucial for Biopharmaceutical Manufacturing?
Viral inactivation has become a cornerstone of biopharmaceutical production, ensuring that biologic drugs, including vaccines, monoclonal antibodies, and plasma-derived therapies, meet the highest safety standards. Regulatory agencies such as the FDA, EMA, and WHO have stringent guidelines mandating viral inactivation to prevent contamination and ensure patient safety. With the increasing reliance on biologics for the treatment of chronic diseases and autoimmune disorders, the demand for effective viral inactivation methods is soaring. Traditional methods such as solvent/detergent treatment, heat inactivation, and low pH inactivation continue to be widely used, while novel technologies, including UV-C irradiation and nanotechnology-based viral removal systems, are gaining traction to enhance the efficiency of bioprocessing workflows.

What Innovations Are Shaping the Future of Viral Inactivation?
Technological innovations are revolutionizing viral inactivation techniques, improving process efficiency and ensuring compliance with evolving regulatory requirements. High-throughput and automated viral inactivation platforms are reducing process variability and improving scalability in large-scale biopharmaceutical production. The integration of AI and machine learning into bioprocessing workflows is optimizing inactivation parameters, enhancing reproducibility, and minimizing the risk of batch failures. Single-use bioprocessing systems are further driving advancements in viral inactivation, providing flexibility and cost-effectiveness while reducing cross-contamination risks. Additionally, advancements in filtration and chromatography techniques are enabling more precise and efficient viral removal without compromising product yield and quality.

How Is the Biopharmaceutical Industry Driving Demand for Viral Inactivation?
The surge in monoclonal antibody and recombinant protein production has significantly boosted demand for viral inactivation solutions, as pharmaceutical companies seek to enhance product safety and accelerate regulatory approvals. The increasing development of cell and gene therapies is also reinforcing the need for advanced viral clearance and inactivation technologies to ensure the integrity of these highly sensitive therapies. Furthermore, the rise of contract development and manufacturing organizations (CDMOs) in biopharmaceutical production is increasing outsourcing of viral inactivation services, allowing biopharma firms to focus on drug development while ensuring stringent safety standards. With global vaccine development efforts intensifying, particularly in response to pandemics and emerging infectious diseases, viral inactivation remains a fundamental step in ensuring vaccine safety and efficacy.

The growth in the viral inactivation market is driven by several factors, including the expanding biologics pipeline, advancements in inactivation technologies, and increasing regulatory emphasis on biopharmaceutical safety. The adoption of single-use bioprocessing and automated viral clearance platforms is accelerating process efficiency while reducing contamination risks. Additionally, the rise of contract manufacturing is propelling demand for specialized viral inactivation services, creating new growth opportunities in the sector. The growing need for robust inactivation techniques in cell and gene therapy production is further fueling market expansion. As biopharmaceutical companies continue to invest in next-generation therapeutics, the demand for innovative and scalable viral inactivation solutions is expected to rise, ensuring sustained market growth.

SCOPE OF STUDY:

The report analyzes the Viral Inactivation market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Component (Kits & Reagents Component, Systems & Accessories Component, Services Component); Application (Vaccines & Therapeutics Application, Stem Cell Products Application, Blood & Blood Products Application, Tissue / Tissue Products Application, Cellular & Gene Therapy Application); End-Use (Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Research Institutes End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

SELECT PLAYERS -

• Charles River Laboratories International, Inc.
• Clean Cells Inc.
• Danaher Corporation
• Merck KgaA
• Parker Hannifin Corporation
• Rad Source Technologies, Inc.
• Sartorius AG
• SGS Group (SGS SA)
• Texcell, Inc.
• V.I.P.S. SA
• WuXi AppTec Group

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more